Rhythm Pharmaceuticals' application for expanding the use of IMCIVREE (setmelanotide) to treat children as young as 2 with Bardet-Biedl syndrome or POMC/LEPR deficiency has been accepted for priority review by the FDA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing